BRCA1 and triple-negative breast carcinoma: Cancers defective in DNA repair, specifically cancers with mutations in the breast cancer associated BRCA1 and BRCA2 genes and triple-negative breast cancer (which shares molecular and pathologic features with BRCA1-related breast cancers) appear to be particularly sensitive to inhibition of PARP-1 [58].